Drug delivery company Acrux has warned it is at risk of missing its next milestone payment from distributor Eli Lilly as concerns about a potential link between testosterone replacement therapy and heart failure hurt US sales.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Drug delivery company Acrux has warned it is at risk of missing its next milestone payment from distributor Eli Lilly because concerns about a potential link between testosterone replacement therapy and heart failure have hampered sales in the US.
Acrux’s lead product is Axiron, an underarm spray that is used to treat low or no testosterone in men.
Fetching latest articles
Original URL: https://www.afr.com/companies/healthcare-and-fitness/acrux-falls-15pc-on-sales-warning-20140428-ihycf